© All rights reserved to Barnea Jaffa Lande & Co. Law offices

Andrey Yanai
Adv. Andrey Yanai

Electra City Tower
58 Harakevet St.
Tel Aviv
6777016

Practice areas:

Andrey Yanai

Andrey, a lawyer in the firm’s Capital Market Department, specializes in advising private and public companies, with an emphasis on dual companies.

Andrey regularly accompanies Israeli and foreign companies in the areas of capital markets, commercial law, public offerings, mergers and acquisitions, joint ventures, and corporate governance. He also represents the firm’s clients before the Israel Securities Authority.

 

In addition, Andrey accompanies blockchain technology companies in all aspects of their commercial activities, including the issuance of digital currencies of all kinds (ICOs and STOs), intellectual property, technology commercialization, and privacy.

 

Prior to joining the firm, Andrey worked at the Bank of Israel, where he accompanied structural reforms and regulatory processes in the banking and capital market fields.

Education:


Tel-Aviv University (LL.B, BA in economics) 2010

Admission:


Member of the Israel Bar Association since 2011



News and updates - Andrey Yanai:


March 27, 2017

Medigus Ltd. Completed a Nasdaq IPO

Barnea & Co. represented a group of US underwriters, led by H.C. Wainwright & Co., LLC, in the process of submission of Medigus Ltd. of a prospectus for the Nasdaq listing. Medigus raised USD 7.5 million and will be traded on Nasdaq in parallel with its listing on the Tel Aviv Stock Exchange. Medigus Ltd is an Israel-based company active in the medical sector. It specializes in developing endoscopic procedures and devices.

August 1, 2016

Cellect Biotechnology Completed a Nasdaq IPO

On 31st July 2016 Cellect Biotechnology announced that it has completed its Nasdaq IPO, raising $8.4 million. Cellect Biotechnology will be traded on Nasdaq in parallel with its listing on the Tel Aviv Stock Exchange. Barnea & Co. represented a group of US underwriters, led by H.C. Wainwright & Co., LLC, in the process of submission by Cellect Biotechnology of a prospectus for the Nasdaq listing. Cellect Biotechnology develops innovative technologies in the stem cells sphere.

June 30, 2016

Proposal to reconsider the activist regulatory model of the Israel Securities Authority

An article by Adv. Zvi Gabbay and Andrey Yanai on the proposal to reconsider the activist regulatory model of the Israel Securities Authority applied to the public companies, allowing them to enjoy wider business and legal maneuvering room.

See all news of Andrey Yanai >

Practice areas:
Enter your email for newsletter sign up: